尤物视频污,99热99热99超碰,精品久久久久女少妇,少妇精品无码,日B视屏久久香色,亚洲美女午夜福利av,国产美女被操,国产九九精品,国产久久色情

Dalian Yongda Suli Pharmaceutical Co., Ltd. was established in December 2020 as a joint investment by Suli Pharmaceutical Technology Jiangyin Co., Ltd., a wholly-owned subsidiary of "Suli Shares," and Jiangsu Yongda Pharmaceutical Co., Ltd.

Jiangsu Yongda Pharmaceutical, founded in 2001, is a pharmaceutical enterprise specializing in the production, sales, and service of chemical raw materials and intermediates. Equipped with high-quality facilities and advanced testing instruments, the company implements a quality management system that meets domestic and international GMP standards. Leveraging its expertise in high-pressure hydrogenation reactions and enzymatic catalysis, along with its large-scale production capabilities, it has become a key production base and major supplier of quinolone antibacterial raw materials, nateglinide raw materials, perindopril raw materials, and their intermediates, both domestically and internationally. The company enjoys a strong reputation and recognition among customers worldwide, with its products sold in numerous countries and regions. Five of its raw materials have passed national GMP certification.

Suli Pharmaceutical Technology Jiangyin Co., Ltd., a wholly-owned subsidiary of Suli Shares, is a CRO/CDMO service company offering integrated drug research and development, pilot-scale testing, and production services. It provides clients with product synthesis development and production from laboratory-scale grams to ton-scale quantities. With extensive experience and technical expertise in process development, Suli Pharmaceutical has built a solid reputation in the industry and established partnerships with many innovative drug companies domestically and internationally. The company has also developed an asymmetric catalytic chiral synthesis technology platform and a special fluorination reagent development platform to accelerate the industrialization of cutting-edge technologies and innovations, using these advancements to synthesize chiral and fluorinated structures for a wider range of new drug molecules.

Dalian Yongda Suli Pharmaceutical Co., Ltd. will combine the strengths of its parent companies to create a larger-scale production base for raw materials and intermediates with enhanced quality and safety management. It will continue to provide customers with stable-quality, cost-effective, and superior-service catalog products and CDMO services. The company commenced trial production in the first quarter of 2024 and plans to pass the National Medical Products Administration's GMP audit by 2025. Additionally, it will submit DMF applications for multiple raw material products and aims to pass U.S. FDA audits as soon as possible. The company will strictly implement an EHS management system, adhere to national standards and park requirements for waste treatment, and prioritize employee health and safety, fulfilling its corporate social responsibilities while ensuring quality and quantity.

With support from its Shanghai R&D center, the company will continue to expand the construction of new technology platforms, including high-pressure hydrogenation, enzymatic catalysis, chiral synthesis, and novel fluorination. Leveraging the process development experience of its R&D team, it will provide domestic and international clients with comprehensive CRO/CDMO services, including route design, process development, process safety assessment, and production scale-up.

Yongda Suli Pharmaceutical will continuously pursue innovation to achieve green, efficient, and economical synthetic processes. Adhering to the principles of "lean management and strict control," it aims to produce "trustworthy medicines" for society, benefiting the people and contributing to human health.